Sweden-based Modus Therapeutics Holding AB has named Claes Lindblad as its new chief financial officer, it was reported on Friday.

Lindblad has more than 20 years of pharmaceutical and medtech experience in a range of sales and marketing, operational and financial roles. He has served as the CFO of OssDsign. He has served as the Swedish country manager for ConvaTec. He rejoined ConvaTec in 2012, from Nycomed/Takeda, where he was responsible for the sales of the company's OTC and generics portfolio in Sweden. He has served in senior positions with increasing responsibility at ConvaTec across the Nordic region.

John Ohd, Modus Therapeutics CEO, said, 'I am very pleased to welcome Claes to Modus. His significant financial and operational experience will be invaluable as we look to develop sevuparin as an important new treatment for sepsis/septic shock, and other systemic inflammatory conditions. Severe inflammation is a complication that millions of patients suffer from because of serious medical conditions such as infection, trauma and major surgery. This is exemplified by sepsis that causes the patient's condition to deteriorate rapidly increasing the risk of death due to vital function and organ failure, is one of the costliest conditions to treat in the hospital care setting.'